Cannabis
Medicinal cannabis company Cronos Australia makes ASX debut
Australian medicinal cannabis company Cronos Australia (ASX: CAU) has started trading on the Australian Securities Exchange, following a successful AUD$20 million initial public offering (IPO) of shares.
Cronos Australia raised AUD$20 million from institutional and sophisticated investors in October, offering 40 million shares at AUD$0.50 each. The Company’s indicative market capitalisation at the close of the offer was approximately AUD$64.4 million.
Cronos Australia trades under the ASX ticker code of CAU.
“The ASX listing is a significant milestone in the life of Cronos Australia, and we look forward to delivering on our vision of being a leading health and wellness company in the Asia-Pacific Region through a portfolio of successful, premium cannabinoid brands and products,” Shane Tanner, Chairman of Cronos Australia noted.
Cronos Australia is pursuing an asset-light business model under which the cultivation of medicinal cannabis and the manufacturing of medicinal cannabis products is expected to be outsourced to other companies both domestically and overseas.
Cronos Australia intends to import and sell Cronos Group’s PEACE NATURALS™ medicinal cannabis products, which are sold in Canada and Germany.
Cronos Australia Chief Executive Officer, Rodney Cocks, said, “Cronos Australia is excited to join this fast-emerging sector as Australia’s newest listed medical cannabis company. Our asset-light business model, backing of Cronos Group and Asia-Pacific focus give the Company a unique proposition in our market.
“We look forward to providing future updates to the market as the funds raised are deployed to accelerate the development and commercialisation of our portfolio of medicinal cannabis products.”
Cronos Australia was established as a 50:50 joint venture between Cronos Group and NewSouthern Capital. After the issue of new shares, Cronos Group holds approximately 31 per cent of the issued capital of Cronos Australia.
Subject to the terms of an IP license agreement between Cronos Group and Cronos Australia, Cronos Australia has access to certain elements of Cronos Group’s intellectual property.
The Australian market for medicinal cannabis is still in its early stages, reflecting complex legislation and regulation. However, patient access is expected to continue growing as legislation evolves and markets open.
The IPO offer was fully underwritten by Lead Manager Bell Potter Securities Limited.
SOURCE Cronos Australia
Cannabis
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
Cannabis
Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect
Cannabis
Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand
-
Cannabis2 weeks ago
Right On Brands, Inc. Continues Rollout, Announces 13th Store Opening
-
Cannabis2 weeks ago
Avicanna Announces Completion of Topical Gel Observational Real-World Evidence Study
-
Cannabis2 weeks ago
Geopulse Exploration, Inc. Acquires 50% of ATC Services
-
transfer1 week ago
IMC to transfer its Oranim Pharmacy shares back to the seller
-
Cannabis1 week ago
Right on Brands Announces Major Product Line Expansion via HONEY® Brands
-
Cannabis6 days ago
Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect
-
Cannabis7 days ago
Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand
-
CCELL®1 week ago
CCELL Launches Environmentally Conscious Eco Star AIO Vaporizer